We are live on
!
Find out more
LVTX
LAVA Therapeutics
LVTX
LVTX
Delisted
LVTX was delisted on the 20th of November, 2025.
20 hedge funds and large institutions have $44.3M invested in LAVA Therapeutics in 2021 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 7 reducing their positions, and 1 closing their positions.
New
Increased
Maintained
Reduced
Closed
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
5% more funds holding
Funds holding: 19 → 20 (+1)
0.63% less ownership
Funds ownership: 31.88% → 31.24% (-0.63%)
9% less capital invested
Capital invested by funds: $48.6M → $44.3M (-$4.35M)
71% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 7
Holders
20
Holders Change
+1
Holders Change %
+5.26%
% of All Funds
0.31%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
2
Reduced
7
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$28.4K |
| 2 |
Axa
Paris,
France
|
+$18.1K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$11.5K |
| 4 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$1.97K |
Top Sellers
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$508K |
| 2 |
Millennium Management
New York
|
-$201K |
| 3 |
AWG
Alpha Wave Global
New York
|
-$125K |
| 4 |
BFM
Boothbay Fund Management
New York
|
-$109K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$59.5K |
